Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

News • Neuroscience

Possible biomarker for suicidal thoughts identified

Researchers identified a possible biomarker linked to severe suicidal thoughts. It may also help explain why some people recover, opening a new path for research into resilience and prevention.

News • iPSC-derived assembloids

Heart valve organoid to advance understanding of cardiac conditions

In a first for the field, a team has grown heart valves on organoids. This work is an important step toward better understanding—and treating—a number of serious heart disorders.

Putting β-glucan testing into everyday practice for fungal infections

Invasive fungal infections are notoriously hard to catch early, and even harder to rule out with confidence. At CHU Bordeaux, Dr Frédéric Gabriel has spent years refining how his lab uses…